Please login to the form below

Not currently logged in
Email:
Password:

Internis appoints Sandoz's Paul Tredwell

He joins the UK bone disorder-focused start-up as chief operating officer

Internis Paul TredwellInternis has poached Sandoz's former head of biopharmaceuticals Paul Tredwell to serve as its chief operating officer.  

Tredwell joins the UK bone disorder-focused start-up after serving at Sandoz for four years, during which time he set up a new division in the UK and was directly responsible for managing the sales, marketing and medical functions.  

Prior to his time with the firm, which operates as Novartis' generics division, Tredwell spent eight years with Shire in senior sales and marketing positions. These included leading the UK specialist sales teams as well as its commercial and NHS teams.  

Paul began his career in the pharmaceutical industry with Galen 16 years ago where he served as area sales manager.  

In his new role Tredwell will be tasked with driving sales of Internis' calcium products FultiumD3 and Accrete D3, as well as a number of new products the firm plans to introduce early next year.  

He will report to Internis' joint CEO Alan Walker who said: "We are delighted to have Paul Tredwell join our team. Paul is a recognised global leader in his field.  

“His skills, knowledge and extensive experience in the industry, as well as his ability to deliver results, make him the ideal candidate to lead Internis into the next exciting phase of its development."

27th August 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics